Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | PLA2G2A | P14555 | 3/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CCR3 | P51677 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6487420 | 0.86 | KDM4E (0.63) | GAAPLA2G2ASIGMAR1KDM4ELMNA | |
| SCHEMBL6480409 | 0.83 | PLA2G2A (0.60) | NPC1RAB9ATP53GAAHPGD | |
| SCHEMBL22802254 | 0.81 | ALDH1A1 (0.64) | NPC1RAB9ATP53GAAHPGD | |
| SCHEMBL3594477 | 0.81 | LMNA (0.61) | NPC1RAB9ATP53HPGDALDH1A1 | |
| SCHEMBL6479419 | 0.80 | PLA2G2A (0.57) | PLA2G2ASIGMAR1 | |
| SCHEMBL12040820 | 0.80 | CCR3 (0.70) | SIGMAR1KDM4ELMNACCR3 | |
| SCHEMBL22802252 | 0.80 | ALDH1A1 (0.66) | NPC1RAB9ATP53GAAHPGD | |
| SCHEMBL8723260 | 0.80 | CCR3 (0.70) | SIGMAR1KDM4ELMNACCR3 | |
| SCHEMBL15800706 | 0.80 | CCR3 (0.70) | SIGMAR1KDM4ELMNACCR3 | |
| SCHEMBL4555241 | 0.78 | ALDH1A1 (0.60) | NPC1RAB9ATP53GAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1612868-A | Ethylene derivative and use as phophatidase | YANG JI CHEMICAL COMPANY LTD (KR) | 2005-05-04 | — | — | CN | disclosed |
| US-20050075345-A1 | Novel inhibitor compounds specific of secreted non-pancreatic human a<sb>2</sb>phospholipase of group II | YANG JI CHEMICAL COMPANY LTD. (KR) | 2005-04-07 | — | — | US | disclosed |
| EP-1456186-A1 | NOVEL INHIBITOR COMPOUNDS SPECIFIC OF SECRETED NON-PANCREATIC HUMAN A SB 2 /SB PHOSPHOLIPASE OF GROUP II | Yang Ji Chemical Company Ltd. (KR) | 2004-09-15 | — | — | EP | disclosed |
| WO-2003048139-A1 | NOVEL INHIBITOR COMPOUNDS SPECIFIC OF SECRETED NON-PANCREATIC HUMAN A2 PHOSPHOLIPASE OF GROUP II | YANG JI CHEMICAL COMPANY LTD. (KR) | 2003-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075345-A1 | Novel inhibitor compounds specific of secreted non-pancreatic human a<sb>2</sb>phospholipase of group II | AMY2A, PNLIP, IAPP | NPC1 2640/4885RAB9A 599/4885TP53 3676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.